The TSC1/TSC2–mTOR axis: disease biology and target architecture

Tuberous sclerosis complex is an autosomal dominant disorder caused by loss-of-function mutations in either TSC1 (encoding hamartin) or TSC2 (encoding tuberin). The hamartin-tuberin protein complex functions as a critical GTPase-activating protein (GAP) for Rheb, suppressing mTORC1 activity. Loss of either gene causes Rheb-GTP to accumulate, driving constitutive mTORC1 hyperactivation, dysregulated cell growth, and the multi-organ manifestations — angiomyolipoma (AML), lymphangioleiomyomatosis (LAM), cortical tubers, subependymal giant cell astrocytomas, epilepsy, intellectual disability, and autism — that define the clinical syndrome.

The molecular target architecture is more complex than the mTORC1 node alone. Patents from POSTECH Academy Industry Foundation describe a PLD2–Rheb–mTOR axis, identifying phosphatidic acid (PA) as a mediator coupling Rheb to mTOR kinase activation — a discrete upstream regulatory node distinct from TSC1/TSC2. Yonsei University filings identify leucyl tRNA synthetase (LRS) and its interaction with Rag GTPases as an amino-acid-sensing mechanism governing mTORC1 activation, with direct relevance to epilepsy and brain diseases. Harvard University patents (now inactive) additionally link TSC2 deficiency to endoplasmic reticulum (ER) stress and unfolded protein response activation as a pathological mechanism independent of direct mTOR signalling.

Next-generation mTORC1-selective inhibitors: the dominant competitive axis

Rapalogues — rapamycin (sirolimus), everolimus, and temsirolimus — are the most extensively represented modality in the TSC patent dataset, and mTORC1 selectivity has emerged as the primary competitive differentiator driving second-generation development. A central concern across multiple filings is that chronic dosing with first-generation rapalogues produces off-target suppression of mTORC2, motivating the development of compounds with substantially improved mTORC1:mTORC2 selectivity ratios (characterised by high ΔpIC50: mTORC1 pIC50 minus mTORC2 pIC50).

Eobian Pharmaceuticals (also identified as Aiovian Pharmaceuticals) holds active patents in China and Japan on mTORC1-selective modulators, with TSC as the lead indication and high selectivity over mTORC2 as the stated differentiating feature. Navitor Pharmaceuticals — whose assets appear to have been acquired and now appear under Anaclia Therapeutics and Janssen Pharmaceutica — holds patents across Taiwan, Japan, and China on rapamycin analogs with modulated mTORC1 specificity, explicitly addressing TSC, focal cortical dysplasia, and PTEN-related diseases. Delos Pharmaceuticals has filed across multiple jurisdictions on rapamycin analogs with improved mTORC1 specificity, listing LAM and TSC among target indications. Novartis AG holds a pending Hong Kong patent covering rapamycin derivatives specifically for neurocutaneous disorders including TSC — consistent with the established clinical trajectory of everolimus (RAD001) within that organisation.

Two further chemical classes extend the mTOR inhibitor landscape beyond rapalogues. Yonsei University filings describe compounds based on LRS–RagD interaction inhibition (Chemical Formula 1 compounds) with specific claims covering epilepsy as an mTOR pathway–related brain disease, providing a distinct druggable entry point upstream of mTORC1. Biocodex holds active Japanese patents on small molecule compounds for diseases associated with mTOR pathway dysregulation, explicitly citing TSC, while Pitney Pharmaceuticals discloses aminoacetonitrile derivatives (AADs) as mTOR pathway modulators.

“Multiple assignees are specifically engineering compounds with high mTORC1:mTORC2 selectivity ratios — the ΔpIC50 approach — signalling that chronic tolerability in a lifelong-management condition is the defining competitive axis in the TSC small-molecule space.”

AAV gene therapy for TSC2: engineering around the cargo-size barrier

Two independent gene therapy programs are converging on the same technical problem: the TSC2 coding sequence is approximately 5.4 kb, which strains or exceeds the packaging capacity of standard AAV capsids. The solutions being pursued — condensed Tuberin and micro-Tuberin protein engineering — define the current IP frontier in TSC gene therapy, and the independent arrival of two major programmes at this same constraint confirms that cargo-size engineering is the primary technical barrier for AAV-based TSC2 gene replacement, as noted by authorities including the NIH in the context of large-gene AAV delivery challenges.

BridgeBio Gene Therapy Research holds the most advanced gene therapy IP in this dataset. Their approach, covered by a Canadian patent filed in 2022 and a pending US patent filed in 2024, uses a recombinant AAV carrying a condensed Tuberin (cTuberin) expression cassette within an AAV capsid. The three-year gap between the originating Canadian filing and the pending US application is consistent with continued IND-enabling work being in progress, though no clinical signal is explicitly described in the retrieved records.

Nationwide Children’s Hospital Research Institute filed a 2024 WO patent on protein-engineered micro-Tuberin gene therapy candidates — engineered truncated tuberin constructs that are smaller than wild-type Tuberin but retain all functional domains. This 2024 filing is among the most recent in the dataset and signals active pre-IND gene therapy development at a second major institution. Earlier-generation concepts using AAV9 vectors encoding TSC1 or TSC2 appear in patents by Lo, Loon-Tzian (WO 2011) and TheRaMind Research LLC (US 2012), providing prior-art context for the current programmes.

Cold Spring Harbor Laboratory holds patents (Canada 2017, EP 2018) on a mechanistically distinct genetic approach: antisense oligomers targeting TSC2 pre-mRNA splicing or expression to restore functional tuberin protein levels in patients with TSC2 haploinsufficiency. Rather than delivering an exogenous TSC2 construct, the ASO strategy aims to maximise expression from the patient’s remaining functional allele. The inactive status of the EP patent suggests IP prosecution challenges, though the scientific rationale retains relevance. This ASO approach parallels strategies being explored for other haploinsufficiency disorders, consistent with broader trends documented by WHO in rare disease genomic medicine.

Beyond mTOR: four mechanistically distinct approaches to TSC epilepsy

TSC-related epilepsy is refractory in a significant proportion of patients, and the retrieved patent dataset reveals four mechanistically distinct anti-epilepsy approaches in active prosecution — reflecting clinical recognition that mTOR suppression alone is insufficient for seizure control in many individuals. This multimodal epilepsy pipeline is notable because three of the four approaches operate entirely independently of mTOR pathway correction, targeting GABAergic, glutamatergic, and neuroinflammatory mechanisms instead.

Ganaxolone — GABA-A positive allosteric modulation

Marinus Pharmaceuticals holds four patents across WO, CA, AU, and US jurisdictions (2021–2024) covering ganaxolone — a synthetic pregnenolone neurosteroid and positive allosteric modulator of GABA-A receptors — specifically for TSC-related epilepsy. The mechanism is distinct from mTOR inhibition: ganaxolone suppresses seizure activity through GABAergic potentiation rather than correcting the upstream mTOR pathway overactivation. The sequential US continuation filings (PCT 2020 → US 2022 → US 2023 → US 2024), alongside parallel WO, CA, and AU filings, represent a continuation chain spanning four years consistent with an active clinical programme. The multi-jurisdiction geographic breadth and sustained prosecution signal commercial-stage IP development.

mGlu5 negative allosteric modulation

Noema Pharma AG holds pending patents in New Zealand (2021) and Israel (2023, two variants) for the mGlu5 negative allosteric modulator (NAM) 2-chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine in TSC. This glutamatergic approach targets metabotropic glutamate receptor 5, addressing the excitatory/inhibitory imbalance underlying epilepsy in TSC without directly engaging the mTOR pathway. The approach is consistent with broader research into mGlu5 modulation for neurodevelopmental disorders, a direction that has attracted attention across the wider rare-disease field.

TLR4 inhibition — neuroinflammation as an epilepsy target

The National Tuberous Sclerosis Association, Inc. holds a WO patent (2019) describing TLR4 inhibitor administration for TSC treatment, including epilepsy and LAM. This positions neuroinflammatory signalling via toll-like receptor 4 as a therapeutic target in TSC, linking innate immune activation to both epileptogenesis and hamartomatous lesion progression. It is notable that a disease advocacy organisation holds a therapeutic patent in this space, reflecting the translational research investment of patient organisations in rare disease drug development — a trend documented by WIPO in its analysis of rare disease IP activity.

Heat shock protein inhibitors — neuronal ciliation as a novel mechanism

The Children’s Medical Center Corporation (Boston Children’s Hospital) holds WO (2021) and US (2023) patents covering Hsp (heat shock protein) inhibitors combined with mTOR inhibitors for TSC and mTORopathies. The mechanistic rationale involves normalisation of neuronal ciliation (ciliostasis), which is disrupted in TSC and contributes to cortical tuber formation, epilepsy, and neurodevelopmental sequelae. This represents a dual-pathway intervention concept that bridges neuroprotection with mTOR suppression, and the neuronal ciliopathy angle is among the most mechanistically novel directions in the dataset.

Combination strategies and emerging pipeline directions

The TSC pipeline is increasingly characterised by combination strategies that acknowledge the incomplete efficacy of mTOR monotherapy and seek to extend the commercial relevance of established agents. At least three distinct combination rationales are represented in active or pending patent filings, alongside several emerging mechanistic directions that remain at an early stage.

Cannabidiol plus everolimus for TSC seizures

GW Research Limited holds pending Israeli patents (filed 2022) describing methods of treating TSC seizures with cannabidiol (CBD) combined with everolimus, including dose-reduction regimens specifying at least a 10% everolimus dose reduction when co-administered with CBD. The formulation of dose-adjustment language in these patents implies the combination has been evaluated in a clinical context where drug-drug interaction management has been encountered — likely related to CBD’s CYP3A4 inhibitory effects on everolimus metabolism, which would elevate everolimus exposure and necessitate dose reduction. This mechanistic language suggests both pharmacokinetic and pharmacodynamic rationales for the combination.

mTORC1 plus MDK (midkine) dual targeting

Brigham and Women’s Hospital holds a pending US patent (2025) and a WO patent (2023) proposing dual targeting of mTORC1 and MDK (midkine, a heparin-binding growth factor) for TSC-associated AML and LAM. The identification of MDK as a co-target with mTORC1 — potentially driving resistance to rapalogue monotherapy in these manifestations — signals that mTOR monotherapy inadequacy is being addressed through rational co-target identification. This approach parallels combinatorial strategies in oncology where single-pathway inhibition is insufficient.

PARP1 inhibition as synthetic lethality in TSC2-deficient cells

Brigham and Women’s Hospital holds a WO 2015 patent identifying PARP1 as upregulated in TSC2-deficient cells. Since TSC2 regulates PARP1 expression, PARP1 inhibition is proposed as a synthetic-lethal-like strategy for TSC2-deficient tumours including LAM. This concept parallels the established BRCA1/2-PARP inhibitor paradigm in oncology and, while the original filing predates the most recent dataset entries, the approach could be extended to TSC-LAM in combination with mTOR inhibitors.

APE1 inhibitors — a DNA repair angle on TSC

Indiana University Research and Technology Corporation holds a WO 2018 patent proposing APE1 inhibitors (APX3330, APX2009) as TSC therapeutics, linking DNA repair pathway dysregulation to TSC disease progression. This direction remains at an early stage within the dataset but represents an epigenetic/DNA repair angle on TSC pathophysiology distinct from all other retrieved modalities. According to EPO filing records, this WO filing has not generated a large continuation family, suggesting the approach remains exploratory.

ER stress modulation — early-stage concept

Harvard University (President and Fellows of Harvard College) holds multiple now-inactive patents (WO 2007, EP 2008, US 2010, US 2014) on ER stress modulation for TSC treatment, using chemical chaperones (4-phenylbutyric acid/PBA, TUDCA, UDCA, TMAO) to reduce unfolded protein response activation in TSC-deficient cells. TSC2 deficiency was identified as driving ER stress as a distinct disease mechanism, providing a non-mTOR treatment rationale. The inactive status of these patents suggests this early conceptual IP was not advanced commercially, though the mechanistic insight retains scientific relevance.

“Combination patent filings — CBD plus everolimus, mTORC1 plus MDK — are emerging as a strategy to extend IP life around everolimus and provide freedom-to-operate frameworks for combination regimens, reflecting the commercial reality that mTOR monotherapy has ceiling effects in TSC.”

Assignee landscape: where novel TSC IP originates

Academic medical centres and dedicated biotechs dominate novel mechanistic IP filings in the TSC patent dataset, with large pharma represented primarily through rapalogue derivatives and combination extensions. Brigham and Women’s Hospital is the most prolific single institutional assignee, holding patents on mTORC1 + MDK combination (2023, 2025), PARP1 inhibition (2015), and rapamycin combination therapy (2014), across WO and US jurisdictions — indicating sustained translational research investment in TSC-associated LAM specifically.

Marinus Pharmaceuticals stands out as the most commercially focused single-indication assignee in the dataset, with all four of its TSC patents directed exclusively to ganaxolone for TSC-related epilepsy. The multi-jurisdiction prosecution across WO, CA, AU, and US — with the most recent continuation filed in November 2024 — signals commercial-stage IP development rather than exploratory filing. BridgeBio Gene Therapy Research represents the most advanced gene therapy IP position, with filings in two jurisdictions and a three-year continuation trajectory consistent with IND-enabling work.

The collective weight of academic institution filings — Harvard, Indiana University, Brigham and Women’s/Harvard Medical School, Children’s Medical Center Corporation, Cold Spring Harbor Laboratory, and Nationwide Children’s Hospital — accounts for the majority of mechanistically novel TSC-directed filings in the dataset. This concentration of early-stage mechanistic IP in academic institutions suggests that licensing or partnership strategies targeting these organisations may offer access to ER stress, PARP1, APE1, ASO, Hsp/ciliation, and combination oncology directions at an early stage, consistent with technology transfer models described by organisations such as OECD in its analyses of academic IP commercialisation in rare diseases.